Status:
COMPLETED
Pharmacoepidemiology and Pharmacogenetics of a Statin Adverse Event
Lead Sponsor:
University of Washington
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Rhabdomyolysis
Eligibility:
All Genders
30+ years
Brief Summary
To conduct a case-control study of factors that increased the risk of rhabdomyolysis, an adverse drug reaction in cerivastatin users
Detailed Description
BACKGROUND: Cerivastatin (Baycol), an HMG-CoA reductase inhibitor (statin), was approved and marketed in early 1998 for the treatment of dyslipidemias. Soon afterwards, suspected adverse drug reactio...
Eligibility Criteria
Inclusion
- Older than 30 years old
Exclusion
- Recent history of trauma
Key Trial Info
Start Date :
September 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
187 Patients enrolled
Trial Details
Trial ID
NCT00241748
Start Date
September 1 2005
End Date
December 1 2011
Last Update
January 5 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Washington
Seattle, Washington, United States, 98101